ATE196091T1 - Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung - Google Patents

Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung

Info

Publication number
ATE196091T1
ATE196091T1 AT97926647T AT97926647T ATE196091T1 AT E196091 T1 ATE196091 T1 AT E196091T1 AT 97926647 T AT97926647 T AT 97926647T AT 97926647 T AT97926647 T AT 97926647T AT E196091 T1 ATE196091 T1 AT E196091T1
Authority
AT
Austria
Prior art keywords
type
chemokine
binding proteins
poxviruses
cbp
Prior art date
Application number
AT97926647T
Other languages
English (en)
Inventor
D Grant Mcfadden
Alexandra Lucas
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of ATE196091T1 publication Critical patent/ATE196091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Catalysts (AREA)
AT97926647T 1996-05-22 1997-05-21 Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung ATE196091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1813796P 1996-05-22 1996-05-22
PCT/US1997/008590 WO1997044054A2 (en) 1996-05-22 1997-05-21 Type-2 chemokine binding proteins and methods of use therefor

Publications (1)

Publication Number Publication Date
ATE196091T1 true ATE196091T1 (de) 2000-09-15

Family

ID=21786445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926647T ATE196091T1 (de) 1996-05-22 1997-05-21 Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung

Country Status (20)

Country Link
EP (1) EP0901379B1 (de)
JP (1) JP2000511535A (de)
KR (1) KR20000015895A (de)
CN (1) CN1226171A (de)
AT (1) ATE196091T1 (de)
AU (1) AU3136197A (de)
BR (1) BR9710028A (de)
CA (1) CA2256568A1 (de)
CZ (1) CZ378998A3 (de)
DE (1) DE69703040T2 (de)
DK (1) DK0901379T3 (de)
ES (1) ES2152095T3 (de)
GR (1) GR3034805T3 (de)
IL (1) IL127166A0 (de)
NO (1) NO985412L (de)
NZ (1) NZ333456A (de)
PL (1) PL330149A1 (de)
PT (1) PT901379E (de)
TR (1) TR199802392T2 (de)
WO (1) WO1997044054A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9916703D0 (en) * 1999-07-16 1999-09-15 Alcami Antonio Viral protein binding compositions and methods
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE500838T1 (de) 2000-09-08 2011-03-15 Amylin Pharmaceuticals Inc ßPSEUDOß-NATIVE CHEMISCHE LIGATION
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
DK1339737T3 (da) * 2000-12-04 2007-10-15 Viron Therapeutics Inc Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
DE10162869A1 (de) * 2001-12-20 2003-07-31 Alexander Cherkasky Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger
GB0304531D0 (en) * 2003-02-27 2003-04-02 Isis Innovation Treatment
WO2004103294A2 (en) * 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
CN113234137B (zh) * 2021-06-21 2022-02-25 华中农业大学 分离自草鱼的CXCL20a蛋白在作为抗菌肽中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646695B2 (en) * 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
US5834419A (en) * 1995-04-19 1998-11-10 The John P. Robarts Institute Chemokine binding protein and methods of use therefor
NZ320889A (en) * 1995-09-29 2000-09-29 Immunex Corp A p35 protein which binds to and inhibits chemokines

Also Published As

Publication number Publication date
DK0901379T3 (da) 2000-12-27
PT901379E (pt) 2001-02-28
CN1226171A (zh) 1999-08-18
WO1997044054A2 (en) 1997-11-27
WO1997044054A3 (en) 1998-05-14
CZ378998A3 (cs) 1999-07-14
EP0901379A2 (de) 1999-03-17
PL330149A1 (en) 1999-04-26
CA2256568A1 (en) 1997-11-27
AU3136197A (en) 1997-12-09
NO985412D0 (no) 1998-11-20
BR9710028A (pt) 1999-08-10
NZ333456A (en) 2000-08-25
HK1017622A1 (en) 1999-11-26
IL127166A0 (en) 1999-09-22
EP0901379B1 (de) 2000-09-06
KR20000015895A (ko) 2000-03-15
NO985412L (no) 1999-01-20
GR3034805T3 (en) 2001-02-28
JP2000511535A (ja) 2000-09-05
DE69703040D1 (de) 2000-10-12
TR199802392T2 (xx) 1999-02-22
ES2152095T3 (es) 2001-01-16
DE69703040T2 (de) 2001-05-03

Similar Documents

Publication Publication Date Title
ATE243526T1 (de) Chemokin bindendes protein und verfahren zu seiner verwendung
DE69703040D1 (de) Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung
ATE226633T1 (de) Bindungsdomänen in notch- und delta-proteinen
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
EP2267015A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
ATE255906T1 (de) Antikörper gegen cd40
WO1997044451A3 (en) Vasoactive amine binding molecules
ID21034A (id) Protein kinase dan penggunaannya
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
EP0588036A3 (de) Zusammensetzung zur Isolierung von Apaminrezeptoren, Apaminbindungsprotein und deren Verwendungen.
DE69738945D1 (de) Rken
SE0003099D0 (sv) Adhesive protein and uses therefore
DK0999849T3 (da) Anvendelse af LBP til sepsisbehandling
DK223290A (da) Hidtil ukendt protein til konstatering af draegtighed hos pattedyr, anvendelse af proteinet til tidlig paavisning af draegtighed og fremgangsmaade til fremstilling af proteinet
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee